Jennifer Falkner
Medical · Sugar Land, TXNPI 1174719595
Payments from drug & device makers
Across 463 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Novo Nordisk$924
- Amgen$866
- Lilly USA, LLC$774
- AbbVie$589
- Boehringer Ingelheim$515
- plus $3K from 37 others
What the payments were for
- Food & beverage$9,208100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,221 in reported general payments places this provider in the 90th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $43,419 |
| TrulicityDulaglutide | 16 | $14,516 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $10,837 |
| JardianceEmpagliflozin | 14 | $9,280 |
| MyrbetriqMirabegron | 13 | $9,104 |
| SynthroidLevothyroxine Sodium | 31 | $2,277 |
| Levothyroxine Sodium | 153 | $1,835 |
| Atorvastatin Calcium | 189 | $1,795 |
| Rosuvastatin Calcium | 96 | $1,439 |
| Olmesartan Medoxomil | 29 | $1,330 |
| Amlodipine Besylate | 164 | $1,112 |
| Ezetimibe | 28 | $960 |
| Metoprolol Succinate | 48 | $902 |
| Losartan Potassium | 104 | $832 |
| Bisoprolol Fumarate | 22 | $822 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $924 | $43,41936 claims |
| Lilly USA, LLCTrulicity | $774 | $14,51616 claims |
| GSKTrelegy Ellipta | $209 | $10,83717 claims |
| Boehringer IngelheimJardiance | $515 | $9,28014 claims |
| Astellas Pharma US IncMyrbetriq | $76 | $9,10413 claims |
| AbbVieSynthroid | $589 | $2,27731 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $12 | $1,835153 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,490 medical providers in Texas.
Other medical in Sugar Land
- Jennifer HendersonSugar Land$19K
- Deanna WallaceSugar Land$17K
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Courtney AldridgeSan Antonio$129K
- Shakira CabreraSan Antonio$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.